Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
Wouter T. Zandee, Tessa Brabander, Anela Blažević, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 9, pp. e3665-e3672
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
Simona Grozinsky‐Glasberg, Joseph Davar, Johannes Hofland, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 7
Open Access | Times Cited: 100
European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours
Ángela Lamarca, Detlef K. Bartsch, Martyn Caplin, et al.
Journal of Neuroendocrinology (2024) Vol. 36, Iss. 9
Open Access | Times Cited: 17
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
Luca Urso, Alberto Nieri, Licia Uccelli, et al.
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1110-1110
Open Access | Times Cited: 27
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Philip E. Harris, Konstantin Zhernosekov
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 38
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
Morticia N. Becx, Noémie S. Minczeles, Tessa Brabander, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5792-5792
Open Access | Times Cited: 31
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
Laure Al Mansour, Louis de Mestier, Magalie Haissaguerre, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 2, pp. 258-263
Open Access | Times Cited: 8
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Jeroen Dekervel, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 129-129
Open Access | Times Cited: 36
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Valentina Ambrosini, Lucia Zanoni, Angelina Filice, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1055-1055
Open Access | Times Cited: 27
Peptide Receptor Radionuclide Therapy
Johannes Hofland, Tessa Brabander, Frederik A. Verburg, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 12, pp. 3199-3208
Open Access | Times Cited: 26
Management of Diarrhea in Patients With Carcinoid Syndrome
Boris G. Naraev, Magnus Halland, Daniel M. Halperin, et al.
Pancreas (2019) Vol. 48, Iss. 8, pp. 961-972
Open Access | Times Cited: 37
New Insights in PRRT: Lessons From 2021
Giulia Puliani, Alfonsina Chiefari, Marilda Mormando, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 17
An ACTH-Producing Neuroendocrine Tumor: Clinical Course of Multidisciplinary Therapy Including Peptide Receptor Radionuclide Therapy – A Case Report
Tomonobu Koizumi, Ai Sato, Kohei Kitajima, et al.
Case Reports in Oncology (2025) Vol. 18, Iss. 1, pp. 181-189
Open Access
Gastrointestinal neuroendocrine tumor syndromes (GI-NETS)
Tetsuhide Ito, Robert T. Jensen
Elsevier eBooks (2025)
Closed Access
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Carcinoid syndrome
Marina Tsoli, Gregory Kaltsas
Elsevier eBooks (2025)
Closed Access
The role of serotonin inhibition within the treatment of carcinoid syndrome
Joel George, John Ramage, Benjamin White, et al.
Endocrine Oncology (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 7
Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms
Johannes Hofland, Wouter W. de Herder
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101787-101787
Open Access | Times Cited: 7
Management of functional neuroendocrine tumors
Amr Wahba, Zi Tan, Joseph S. Dillon
Current Problems in Cancer (2024) Vol. 52, pp. 101130-101130
Closed Access | Times Cited: 2
Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers
Laura Algeri, Lovisa Falkman, Francesca Spada, et al.
ESMO Open (2024) Vol. 9, Iss. 11, pp. 103959-103959
Open Access | Times Cited: 2
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Jelka Kuiper, Eline Zoetelief, Tessa Brabander, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 2
Bronchial Carcinoids: From Molecular Background to Treatment Approach
Marta Araujo‐Castro, Eider Pascual‐Corrales, Javier Molina‐Cerrillo, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 520-520
Open Access | Times Cited: 11
Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome
Anna Koumarianou, Kosmas Daskalakis, Marina Tsoli, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 7
Closed Access | Times Cited: 8
What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature
Elisa Giannetta, Franz Sesti, Roberta Modica, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 10, pp. 1553-1553
Open Access | Times Cited: 8
Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
Iiro Kostiainen, Noora Karppinen, Piia Simonen, et al.
Endocrine (2022) Vol. 77, Iss. 1, pp. 177-187
Open Access | Times Cited: 7
Carcinoid crisis: The challenge is still there
Fernando Guerrero‐Pérez, Inmaculada Peiró, J.L. Vercher-Conejero, et al.
Endocrinología Diabetes y Nutrición (2024) Vol. 71, Iss. 6, pp. 263-270
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top